XNCR Xencor, Inc.
Xencor, Inc. (XNCR) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.3% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Xencor, Inc.
Xencor Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs.
Sector
Healthcare
Industry
Biotechnology